INMAZEB

PeakmAb

atoltivimab, maftivimab, and odesivimab-ebgn

BLAINJECTIONSOLUTIONPriority Review
Approved
Oct 2020
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1

Mechanism of Action

IgG1κ monoclonal antibodies (atoltivimab, maftivimab, and odesivimab) that inhibit Orthoebolavirus zairense [ see ].

Clinical Trials (1)

NCT05202288Phase 2Not Yet Recruiting

Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers

Started Jan 2027
132 enrolled
Ebola Virus Disease